The Rosen Law Firm has initiated a securities class action lawsuit against Mereo BioPharma Group plc, alleging that company leadership made materially false and misleading statements regarding clinical trial results for its investigational drug setrusumab. The complaint targets investors who purchased American Depositary Shares between June 5, 2023 and December 26, 2025, a period during which the firm contends the company misrepresented the efficacy and trial outcomes of the pharmaceutical candidate.
According to the lawsuit, Mereo allegedly expressed confidence in setrusumab's ability to reduce fracture rates while withholding critical information that neither the Phase 3 Orbit nor COSMIC clinical trials achieved their designated primary endpoints. The defendants' statements are claimed to have resulted in artificially inflated share prices during the relevant purchase period, exposing investors to undisclosed material risks.
Affected investors have until April 6, 2026 to petition the court to serve as lead plaintiff in the action. The firm is encouraging shareholders who purchased securities during the alleged misrepresentation period to consult with qualified legal counsel regarding their potential claims and eligibility for compensation under securities law.